145 related articles for article (PubMed ID: 1157247)
21. Platelet survival time following aortic valve replacement.
Steele P; Weily H; Davies H; Ppppas G; Genton E
Circulation; 1975 Feb; 51(2):358-62. PubMed ID: 1112016
[TBL] [Abstract][Full Text] [Related]
22. [Use of miskleron in ischemic heart disease with differing types of hyperlipoproteinemias].
Krivoruchenko IV; Nikul'cheva NG
Kardiologiia; 1976 Jul; 16(7):71-5. PubMed ID: 185448
[TBL] [Abstract][Full Text] [Related]
23. Failure of sulphinpyrazone to affect platelet survival in patients with rheumatic heart valvular disease: a double blind study using 75Se-methionine labeled platelets.
Fabris F; Casonato A; Randi ML; Schivazappa L; Schiavinato L; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(4):594-601. PubMed ID: 6196274
[TBL] [Abstract][Full Text] [Related]
24. One-year trials with halofenate, clofibrate, and placebo.
Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
[TBL] [Abstract][Full Text] [Related]
25. Platelet suppressing drugs in arterial disease.
Blakely JA
Thromb Haemost; 1978 Apr; 39(2):294-303. PubMed ID: 580983
[No Abstract] [Full Text] [Related]
26. [Comparison between combination therapy with clofibrate and beta-pyridylcarbinol and clofibrate monotherapy (author's transl].
Mordasini R; Müller A; Klose G; Middelhoff G; Augustin J; Haase W; Greten H
MMW Munch Med Wochenschr; 1978 Apr; 120(15):525-8. PubMed ID: 206826
[TBL] [Abstract][Full Text] [Related]
27. Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Harker LA; Hirsh J; Gent M; Genton E
Prog Hematol; 1975; 9():229-54. PubMed ID: 766074
[No Abstract] [Full Text] [Related]
28. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
[No Abstract] [Full Text] [Related]
29. Platelet survival time in patients with hypoxemia and pulmonary hypertension.
Steele P; Ellis JH; Weily HS; Genton E
Circulation; 1977 Apr; 55(4):660-1. PubMed ID: 837512
[TBL] [Abstract][Full Text] [Related]
30. Clofibrate and related compounds in hyperlipoproteinaemia. A review.
Gustafson A
Postgrad Med J; 1975; 51(8):suppl 66-71. PubMed ID: 215983
[No Abstract] [Full Text] [Related]
31. Platelet function in coronary artery disease: effects of coronary surgery and sulfinpyrazone.
Cade JF; Doyle DJ; Chesterman CN; Morgan FJ; Rennie GC
Circulation; 1982 Jul; 66(1):29-32. PubMed ID: 6211296
[TBL] [Abstract][Full Text] [Related]
32. Role of blood platelets in coronary artery disease.
Haft JI
Am J Cardiol; 1979 Jun; 43(6):1197-206. PubMed ID: 35967
[TBL] [Abstract][Full Text] [Related]
33. Hypolipidemic effect of tibric acid. A comparison with clofibrate and placebo in type IV hyperlipoproteinemia.
Bielmann P; Brun D; Moorjani S; Gagnon MA; Tétreault L; Lupien PJ
Int J Clin Pharmacol Biopharm; 1977 Apr; 15(4):166-71. PubMed ID: 192685
[TBL] [Abstract][Full Text] [Related]
34. [Clinical and therapeutic evaluation of a new antilipemic substance].
de Aguiar Magano L
Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
[TBL] [Abstract][Full Text] [Related]
35. Clofibrate and niacin in coronary heart disease.
JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963
[No Abstract] [Full Text] [Related]
36. [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].
Arntz HR; Klemens UH; Vollmar LJ; Lang PD
Med Klin; 1978 Dec; 73(49):1731-7. PubMed ID: 723760
[TBL] [Abstract][Full Text] [Related]
37. The current status of platelet suppressive drugs in the treatment of thrombosis.
Hirsh J; Gent M; Genton E
Thromb Diath Haemorrh; 1975 Jun; 33(3):406-16. PubMed ID: 1098213
[No Abstract] [Full Text] [Related]
38. Clofibrate reversal of platelet hypersensitivity in hyperbetalipoproteinemia.
Carvalho AC; Colman RW; Lees RS
Circulation; 1974 Sep; 50(3):570-4. PubMed ID: 4369866
[No Abstract] [Full Text] [Related]
39. [Clofibrate action on the lipoprotein composition in primary type IV and type V hyperlipoproteinemia].
Weisweiler P; Schwandt P
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():398-401. PubMed ID: 206058
[No Abstract] [Full Text] [Related]
40. [Prophylactic value of platelet anti-aggregants in coronary disease].
Verstraete M
Clin Ter; 1979 Oct; 91(2):117-27. PubMed ID: 396098
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
